Ensysce Biosciences (ENSC) Total Current Liabilities (2017 - 2025)

Ensysce Biosciences (ENSC) has reported Total Current Liabilities for 9 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Total Current Liabilities rose 106.95% year-over-year to $4.6 million in Q4 2025; TTM through Dec 2025 was $4.6 million, a 106.95% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, up 106.95% from the prior year.
• Total Current Liabilities was $4.6 million for Q4 2025 at Ensysce Biosciences, up from $2.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $16.5 million in Q4 2021 and troughed at $319180.0 in Q1 2021.
• A 5-year average of $4.9 million and a median of $3.1 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities tumbled 90.87% in 2021 and jumped 2657.66% in 2022, its largest moves.
• Over 5 years, Total Current Liabilities stood at $16.5 million in 2021, then sank by 42.58% to $9.5 million in 2022, then sank by 64.78% to $3.3 million in 2023, then tumbled by 33.78% to $2.2 million in 2024, then surged by 106.95% to $4.6 million in 2025.
• The last three Total Current Liabilities figures came in at $4.6 million (Q4 2025), $2.3 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.